DNAprint Genomics (DNAG)

[chiggah]

S101....


I listened to the presentation in whole.

Richard took a different tact by beginning his talk with a layout of how financing a biotech should take place, and the difficulties that lie therein. He used Biofrontera and the european(german) financing as examples. It was actually quite informative, and the processes along with the approach to eventual bonding need to be very well planned for a biotech
without alot of cash flow, and one of his points was that the situation with the dollar makes eurpean financing look more attractive all the time.

All else was the same; bridge financing, timelines etc.

Then he went into DNAPPharm's two main products, the timeline(2008-2010) and used a conservative spreadsheet to show costs/research/sales thru the next 4 years.

His one main figure for a bond and stockbuyback by 2011 was a overall 50 million dollars. I suppose that meant the amount after the bridge financing and to get us to an IPO by 2011, if not sooner.
He mentioned the IPO and stock buyback twice, but aftre sales begin of our two products.

Sorry, but I'm in a hurry.
I thought it was a good presentation.
He is very keen on financing.
BTW, Cananda just matched our dollar with theirs for the first time in 30 yrs. Looking overseas for our financing is astute and a no-brainer, but is a lot more work for R.G., but he's happy to do it.(travel)
ciao